Crafting a Consensus on Therapeutic Cloning

American scientists seem to have forfeited their chance to convince the government to support research into therapeutic cloning as the source of a new generation of rational therapies. It was not always this way. As a young scientist working at Cold Spring Harbor in the early 1970s, my telephoning Paul Berg at Stanford University concerning his work on recombinant DNA and tumor viruses led to the Asilomar conferences, from which the voluntary moratorium on recombinant DNA work emerged, leading t

Written byRobert Pollack
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

American scientists seem to have forfeited their chance to convince the government to support research into therapeutic cloning as the source of a new generation of rational therapies. It was not always this way. As a young scientist working at Cold Spring Harbor in the early 1970s, my telephoning Paul Berg at Stanford University concerning his work on recombinant DNA and tumor viruses led to the Asilomar conferences, from which the voluntary moratorium on recombinant DNA work emerged, leading to the formation of the NIH's Recombinant DNA Advisory Committee, a model of bioethics at work to this day.

At first sight, it seems too late for revisiting the recombinant-DNA precedent, as President George W. Bush already has issued a ban on federal support for any manipulation of a human egg cell except for fertilization by donor sperm, and then only so that the resulting pre-embryo may be placed in a ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies